Christopher Gill

Associate Professor, Global Health

University of Massachusetts Medical School, MD
Tufts-Sackler School of Graduate Biomedical Studies, MS

  • Office: Crosstown Building, CT370
  • Phone: 617-638-6584
  • Email:


Dr. Gill is an infectious disease specialist by training. From 2002-2008 he was a faculty member of the Department of Global Health at Boston University School of Public Health, engaged in a wide variety of clinical trials and investigations. His research interests have focused on child survival, and include diarrheal diseases, tuberculosis, pneumococcal and meningococcal disease, adherence to HIV medications, and neonatal survival. He was the principal investigator of the Lufwanyama Neonatal Survival Project in Northern Zambia (LUNESP), a prospective, cluster randomized and controlled effectiveness study designed to determine whether training traditional birth attendants to manage several common perinatal conditions could reduce neonatal mortality in the setting of a resource poor country with limited access to healthcare. The results demonstrated that training traditional birth attendants in neonatal resuscitation skills significantly reduces neonatal mortality by approximately 50%. From 2008-end of 2010 he was the Director of the Meningitis ACWY conjugate vaccine clinical trials group at Novartis Vaccines. There he was responsible for the design, implementation and analysis of Phase IIb, III and IV clinical trials in support of the vaccine, and played a key role in licensing this new vaccine in over 33 countries around the world, including the US. In 2011, he rejoined the faculty at the BU Center for Global Health and Development and the BU School of Public Health. Christopher Gill has an MD from the University of Massachusetts Medical School and an MS from Tufts-Sackler School of Graduate Biomedical Studies.

Dr. Gill is the Director of the BUSPH Pharmaceuticals Program, a unique educational offering at BUSPH that aims to educate public health practitioners about the role of pharmaceuticals in public health.  Dr. Gill is also a member of the World Health Organization Collaborating Center on Pharmaceutical Policy (WHOCCPP) which provides research and programs for the improvement of access to essential drugs in developing countries and the development of policies that promote greater affordability and the appropriate usage of these medicines.



Improving Adherence to Antiretroviral Therapy With Triggered Real-time Text Message Reminders: The China Adherence Through Technology Study

Lora L. Sabin, MA, PhD; Mary Bachman DeSilva, MS, ScD; Christopher J. Gill, MS, MD; Li Zhong, MA; Taryn Vian, PhD; Wubin Xie, MPH; Feng Cheng, MPH, MD; Keyi Xu, MD; Guanghua Lan, MD; Jessica E. Haberer, MD; David R. Bangsberg, MD; Yongzhen Li, MD; Hongyan Lu, MD; and Allen L. Gifford, MD

Clinical Science. 2015 Jul; 69(5):551-559.

Can traditional birth attendants be trained to accurately identify septic infants, initiate antibiotics, and refer in a rural African setting?

Christopher John Gill, William B MacLeod, Grace Phiri-Mazala, Nicholas G Guerina, Mark Mirochnick, Anna B Knapp, Davidson H Hamer

Global Health: Science and Practice. 2014 Aug; 2(3):318-327.

Bottlenecks, barriers, and solutions: results from multicountry consultations focused on reduction of childhood pneumonia and diarrhoea deaths

Dr Christopher J Gill MD, Mark Young MD, Kate Schroder, Liliana Carvajal-Velez, Marion McNabb, Samira Aboubaker, Shamim Qazi, and Prof Zulfiqar A Bhutta PhD

The Lancet. 2013 Apr; 381(9876):1487 - 1498.

Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease

Ehimen C. Aneni, Davidson H. Hamer, Christopher J. Gill

Tropical Medicine and International Health. 2013 Mar; 18(3):313-327.

Novel assessment of a novel meningitis B vaccine

Christopher J Gill

The Lancet-Infectious Diseases. 2013 Feb; 13(5):381–382.

Feasibility and Acceptability of a Real-Time Adherence Device among HIV-Positive IDU Patients in China

Mary B. DeSilva, Allen L. Gifford, Xu Keyi, Zhong Li, Cheng Feng, Mohamad Brooks, Mark Harrold, Hu Yueying, Christopher J. Gill, Xie Wubin, Taryn Vian, Jessica Haberer, David Bangsberg, and Lora Sabin

AIDS Research and Treatment. 2013 Jan; 2013:1-6.

Defining efficacy and safety of meningococcal vaccines

Keiser PB, Gill CJ

Clinical Investigations. 2012 Jun; 2(6):603-614.

Costs and Cost-Effectiveness of Training Traditional Birth Attendants to Reduce Neonatal Mortality in the Lufwanyama Neonatal Survival Study (LUNESP)

Lora L. Sabin, Anna B. Knapp, William B. MacLeod, Grace Phiri-Mazala, Joshua Kasimba, Davidson H. Hamer & Christopher J. Gill

PLoS ONE. 2012 Apr; 7(4):1-10.

Persistence of the Immune Response at 5 years of Age Following Infant Immunisation with Investigational Quadrivalent MenACWY Conjugate Vaccine Formulations

Ameneh Khatami, Matthew D. Snape, Elizabeth Davis, Helen Layton, Tessa John, Ly-Mee Yu, Peter M. Dull, Christopher J. Gill, Tatjana Odrjlin, Simon Dobson, Scott A. Halperin, Joanne M. Langley, Shelly A. McNeil, & Andrew J. Pollard

Vaccine. 2012 Mar; 30:2831-2838.

Training Zambian traditional birth attendants to reduce neonatal mortality in the Lufwanyama Neonatal Survival Project (LUNESP)

Christopher J. Gill, Nicholas G. Guerina, Charity Mulenga, Anna B. Knapp, Grace Mazala, & Davidson H. Hamer

International Journal of Gynecology and Obstetrics. 2012 Mar; 1-6.

Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants

Klein, Nicola; Reisinger, Keith; Johnston, William; Odrljin, Tatjana; Gill, Christopher; Bedell, Lisa; Dull, Peter

The Pediatric Infectious Disease Journal. 2012 Jan; 31(1):64-71.

Effect of Training Traditional Birth Attendants on Neonatal Mortality (Lufwanyama Neonatal Survival Project): Randomised Controlled Study

Gill C., Phiri-Mazala G., Guerina N., Kasimba J., Mulenga C., MacLeod W., Waitolo N., Knapp A., Mirochnick M., Mazimba A., Fox M., Sabin L., Seidenberg P., Simon J., Hamer D.

British Medical Journal. 2011 Jun;.

Dispelling the Myths Surrounding Traditional Birth Attendants

Gill C., Hamer D.H., Knapp A.B.

British Medical Journal. 2011 Jun; 343(d):4481.

Neonatal resuscitation and immediate newborn assessment and stimulation for the prevention of neonatal deaths: a systematic review, meta-analysis and Delphi estimation of mortality effect

Anne CC Lee, Simon Cousens, Stephen N Wall, Susan Niermeyer, Gary L Darmstadt, Waldemar A Carlo, William J Keenan, Zulfiqar A Bhutta, Christopher Gill and Joy E Lawn

BMC Public Health. 2011 Apr; 11((Suppl 3):S12):1-19.

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age

Scott A. Halperin, Anil Gupta, Robert Jeanfreau, Nicola P. Klein, Keith Reisinger, Emmanuel Walter, Lisa Bedell, Christopher Gill, Peter M. Dull

Vaccine. 2010 Nov; 28(50):7865–7872.

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

Christopher J Gill, Roger Baxter, Alessandra Anemona, Giuseppe L Ciavarro, and Peter M Dull

Human Vaccine. 2010 Nov; 6(11):881–887.

Using Electronic Drug Monitor Feedback to Improve Adherence to Antiretroviral Therapy among HIV-Positive Patients in China

Sabin L. L., DeSilva M. B., Hamer D. H., Xu K., Zhang J., Li T., Wilson I. B., Gill C. J.

AIDS Behav. 2009 Sep; 14(3):580-9.

High Frequency of Multidrug-Resistant Gram-Negative Rods in 2 Neonatal Intensive Care Units in the Philippines

Litzow J. M., Gill C. J., Mantaring J. B., Fox M. P., MacLeod W. B., Mendoza M., Mendoza S., Scobie R., Huskins C. W., Goldman D. A., Hamer D. H.

Infect Control Hosp Epidemiol. 2009 May; 30(6):543-9.

Importance of Dose Timing to Achieving Undetectable Viral Loads

Gill C. J., Sabin L. L., Hamer D. H., Keyi X., Jianbo Z., Li T., Wu W. J., Wilson I. B., Desilva M. B.

AIDS Behav. 2009 Apr; 14(4):785-93.

Effect of Presumptive Co-Trimoxazole Prophylaxis on Pneumococcal Colonization Rates, Seroepidemiology and Antibiotic Resistance in Zambian Infants: A Longitudinal Cohort Study

Gill C. J., Mwanakasale V., Fox M. P., Chilengi R., Tembo M., Nsofwa M., Chalwe V., Mwananyanda L., Mukwamataba D., Malilwe B., Champo D., Macleod W. B., Thea D. M., Hamer D. H.

Bull World Health Organ. 2009 Jan; 86(12):929-38.

Impact of Enhanced Infection Control at 2 Neonatal Intensive Care Units in the Philippines

Gill C. J., Mantaring J. B., Macleod W. B., Mendoza M., Mendoza S., Huskins W. C., Goldmann D. A., Hamer D. H.

Clin Infect Dis. 2008 Nov; 48(1):13-21.

Barriers to Adherence to Antiretroviral Medications Among Patients Living with HIV in Southern China: a Qualitative Study

Sabin L. L., Desilva M. B., Hamer D. H., Keyi X., Yue Y., Wen F., Tao L., Heggenhougen H. K., Seton L., Wilson I. B., Gill C. J.

AIDS Care. 2008 Nov; 20(10):1242-50.

Impact of Human Immunodeficiency Virus Infection on Streptococcus Pneumoniae Colonization and Seroepidemiology among Zambian Women

Gill C. J., Mwanakasale V., Fox M. P., Chilengi R., Tembo M., Nsofwa M., Chalwe V., Mwananyanda L., Mukwamataba D., Malilwe B., Champo D., Macleod W. B., Thea D. M., Hamer D. H.

J Infect Dis. 2008 Apr; 197(7):1000-5.

Inferiority of Single-Dose Sulfadoxine-Pyrimethamine Intermittent Preventive Therapy for Malaria during Pregnancy among HIV-Positive Zambian Women

Gill C. J., Macleod W. B., Mwanakasale V., Chalwe V., Mwananyanda L., Champo D., Mukwamataba D., Chilengi R., Thea D. M., Hamer D. H.

J Infect Dis. 2007 Nov; 196(11):1577-84.

Two-dose Versus Monthly Intermittent Preventive Treatment of Malaria with Sulfadoxine-pyrimethamine in HIV-seropositive Pregnant Zambian Women

Hamer D. H., Mwanakasale V., Macleod W. B., Chalwe V., Mukwamataba D., Champo D., Mwananyanda L., Chilengi R., Mubikayi L., Mulele C. K., Mulenga M., Thea D. M., Gill C. J.

J Infect Dis. 2007 Nov; 196(11):1585-94.

Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review

Rosen S., Fox M. P., Gill C. J.

PLoS Med. 2007 Oct; 4(10):e298.

The prevalence of HIV, HBV and HCV among Filipino blood donors and overseas work visa applicants

Yumiko Yanase, Takashi Ohida, Yoshitaka Kaneita, Dorothy May D Agdamag, Prisca Susan A Leaño, and Christopher J Gill

WHO Bulletin. 2007 Feb; 85(2):131–137.

Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators

Edward J Mills, Jean B Nachega, David R Bangsberg, Sonal Singh, Beth Rachlis, Ping Wu, Kumanan Wilson, Iain Buchan, and Christopher J Gill, Curtis Cooper

PLos-Medicone. 2006 Nov; 3(11):2039-20674.

Antiretroviral programme in rural Uganda

Christopher J Gill

The Lancet. 2006 Aug; 368(9547):1556-1557.

Response to Bangsberg et al., Regarding our Article ‘No Room for Complacency About Adherence to Antiretroviral Therapy in Africa’

Gill C.J., Hamer D.H., Simon J.L., Thea D.M., Sabin L.L.

AIDS. 2006 Jan; 20(1):141-142.

An Uninvited Dinner Guest

Gill C. J., Hamer D. H.

Clin Infect Dis. 2005 Nov; 41(12):1764, 1810-1.

Species-specific bacteria identification using differential mobility spectrometry and bioinformatics pattern recognition.

Shnayderman M, Mansfield B, Yip P, Clark HA, Krebs MD, Cohen SJ, Zeskind JE, Ryan ET, Dorkin HL, Callahan MV, Stair TO, Gelfand JA, Gill CJ, Hitt B, Davis CE.

Analytical Chemistry. 2005 Sep; 71(18):5930-5937.

No Room for Complacency About Adherence to Antiretroviral Therapy in Sub-Saharan Africa

Gill C. J., Hamer D. H., Simon J. L., Thea D. M., Sabin L. L.

AIDS. 2005 Jul; 19(12):1243-9.

Nightingale in Scutari: her legacy reexamined

Christopher J. Gill

Clinical Infectious Diseases. 2005 Jun; 40(12):1799-1805.

Why Clinicians are Natural Bayesians

Gill C. J., Sabin L., Schmid C. H.

BMJ. 2005 May; 330(7499):1080-3.

Fatal fulminant pancreatitis in a patient chronically treated with candesartan

Gill CJ, Jennings A, Newton J, Schwartz D

Journal of Pharmacy and Technology. 2005 Jan; 21(2):79-82.

Reconsidering Empirical Cotrimoxazole Prophylaxis for Infants Exposed to HIV Infection

Gill C. J., Sabin L. L., Tham J., Hamer D. H.

Bull World Health Organ. 2004 Jul; 82(4):290-7.

Questions Regarding the Effectiveness of Trimethoprim-Sulfamethoxazole (Cotrimoxazole) Prophylaxis in African Children

Gill C. J., Hamer D., Thea D. M.

Clin Infect Dis. 2003 Sep; 37(6):863-4; author reply 864.

“Doc, There’s a Worm in my Stool”: Munchausen Parasitosis in a Returning Traveler

Gill C. J., Hamer D. H.

J Travel Med. 2003 Sep; 9(6):330-2.

Diagnostic Accuracy of Stool Assays for Inflammatory Bacterial Gastroenteritis in Developed and Resource-Poor Countries

Gill C. J., Lau J., Gorbach S. L., Hamer D. H.

Clin Infect Dis. 2003 Jul; 37(3):365-75.

Alfalfa Seed Decontamination in Salmonella Outbreak

Christopher J. Gill, William E. Keene, Janet C. Mohle-Boetani, Jeff A. Farrar, Patti L. Waller, Christine G. Hahn, and Paul R. Cieslak

Emerging Infectious Diseases. 2003 Apr; 4(9):747-479.

Haemophilus aphrophilus Purulent Pericarditis and Tamponade

Christopher J. Gill, MD, Richard A. Mularski, MD

Infections in Medicine. 2003 Jan; 20(1):31-33.

Questions Regarding the Effectiveness of Trimethoprim-Sulfamethoxazole (Cotrimoxazole) Prophylaxis in African Children

Christopher J. Gill, Hamer Davidson, and Donald M. Thea

Clinical Infectious Diseases. 2003 Jan; 37(6):863-864.

Treatment of Staphylococcus Epidermidis Ventriculo-Peritoneal Shunt Infection with Linezolid

Gill C. J., Murphy M. A., Hamer D. H.

J Infect. 2002 Sep; 45(2):129-32.

Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life

Gill CJ, Griffith JL, Jacobson D, Skinner S, Gorbach SL, Wilson IB

Journal of Acquired Immunity Deficiency Syndromes. 2002 Aug; 30(5):485-492.

Foodborne Illnesses

Gill C. J., Hamer D. H.

Curr Treat Options Gastroenterol. 2001 Feb; 4(1):23-38.